After two FDA rejections, tab-cel for a rare post-transplant lymphoma was resubmitted, raising questions about how consistently the FDA judges evidence.
After Two FDA Rejections, Rare Lymphoma Cell Therapy Tab-Cel Is Resubmitted on a Study Design FDA Once Doubted
by | Oct 2, 2026 | Uncategorized | 0 comments
Recent Comments